ondansetron has been researched along with methylprednisolone in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (30.43) | 18.2507 |
| 2000's | 9 (39.13) | 29.6817 |
| 2010's | 7 (30.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| d'Allens, H; Depierre, A; Lebeau, B | 1 |
| Chevallier, B; Marty, M; Paillarse, JM | 1 |
| Bacoyiannis, C; Katsikas, M; Kosmidis, P; Lioni, A; Mylonakis, N; Tsavaris, N | 1 |
| Coiffier, B; Khayat, D; Misset, JL; Votan, B | 1 |
| d'Allens, H; Depierre, A; Giovannini, M; Hédouin, M; Kaluzinski, L; Lebeau, B; Rivière, A; Votan, B | 1 |
| Bushnell, W; Chawla, S; Friedman, C; Hainsworth, J; Hesketh, P; Markman, M; Perez, EA; Reeves, J; Sandbach, J | 1 |
| Athanasiou, E; Dimitrakopoulos, A; Katsikas, M; Koufos, C; Linardaki, G; Tsavaris, NB | 1 |
| Bonneterre, J; Harousseau, JL; Hedouin, M; Ouvry, J; Zittoun, R | 1 |
| Bougouin, C; Crespin-Maillard, F; Favier, M; Kinowski, JM; Maillard, C; Thelcide, C | 1 |
| Bloch, J; Delgado, A; Khayat, D; Meric, JB; Rixe, O | 1 |
| Bassam, A; Pikó, B | 1 |
| Chiu, L; Chiu, N; Chow, E; Chow, R; DeAngelis, C; Lechner, B; Lutz, S; Marta, GN; Mendez, LC; Milakovic, M; Pasetka, M; Popovic, M; Pulenzas, N; Zhang, N | 1 |
4 review(s) available for ondansetron and methylprednisolone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Value of the combination of oral ondansetron with methylprednisolone as soon as the first cure in mild emetogenic chemotherapy. Groupe français d'étude de l'ondansétron].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Female; Humans; Lymphoma; Male; Methylprednisolone; Middle Aged; Nausea; Ondansetron; Quality of Life; Single-Blind Method; Vomiting | 1997 |
[Treatment of tumor therapy-induced nausea and vomiting].
Topics: Anti-Anxiety Agents; Antiemetics; Antineoplastic Agents; Aprepitant; Drug Therapy, Combination; Humans; Methylprednisolone; Metoclopramide; Morpholines; Nausea; Neoplasms; Ondansetron; Practice Guidelines as Topic; Selective Serotonin Reuptake Inhibitors; Vomiting | 2009 |
Latest advances in the management of radiation-induced pain flare, nausea and vomiting.
Topics: Antiemetics; Bone Neoplasms; Dexamethasone; Humans; Methylprednisolone; Musculoskeletal Pain; Nausea; Ondansetron; Palliative Care; Radiotherapy; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2016 |
9 trial(s) available for ondansetron and methylprednisolone
| Article | Year |
|---|---|
A comparison of ondansetron with alizapride plus methylprednisolone in the control of cisplatin-induced emesis. The French Pneumology Group for the Ondansetron Study.
Topics: Antiemetics; Cisplatin; Drug Combinations; Humans; Imidazoles; Methylprednisolone; Ondansetron; Pyrrolidines; Time Factors | 1992 |
Methylprednisolone enhances the efficacy of ondansetron in acute and delayed cisplatin-induced emesis over at least three cycles. Ondansetron Study Group.
Topics: Acute Disease; Adult; Antiemetics; Cisplatin; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methylprednisolone; Middle Aged; Nausea; Ondansetron | 1994 |
Comparison of ondansentron versus ondansentron plus methylprednisolone as antiemetic prophylaxis during cisplatin-containing chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Therapy, Combination; Female; Humans; Male; Methylprednisolone; Middle Aged; Nausea; Ondansetron; Vomiting | 1994 |
[Value of the combination of oral ondansetron with methylprednisolone as soon as the first cure in mild emetogenic chemotherapy. Groupe français d'étude de l'ondansétron].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Female; Humans; Lymphoma; Male; Methylprednisolone; Middle Aged; Nausea; Ondansetron; Quality of Life; Single-Blind Method; Vomiting | 1997 |
The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. The French Ondansetron Study Group.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Double-Blind Method; Drug Therapy, Combination; Humans; Isonipecotic Acids; Methylprednisolone; Middle Aged; Nausea; Neoplasms; Ondansetron; Prognosis; Quality of Life; Vomiting | 1997 |
Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Carboplatin; Cyclophosphamide; Dexamethasone; Double-Blind Method; Female; Granisetron; Humans; Injections, Intravenous; Male; Methylprednisolone; Middle Aged; Nausea; Ondansetron; Vomiting | 1998 |
Antiemetic prophylaxis with ondansetron and methylprednisolone vs metoclopramide and methylprednisolone in mild and moderately emetogenic chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Female; Humans; Male; Methylprednisolone; Metoclopramide; Middle Aged; Ondansetron; Vomiting | 1999 |
[Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination].
Topics: Adult; Antiemetics; Breast Neoplasms; Double-Blind Method; Drug Therapy, Combination; Female; Hematologic Neoplasms; Humans; Lorazepam; Male; Methylprednisolone; Middle Aged; Nausea; Ondansetron; Patient Satisfaction; Quality of Life; Vomiting | 2000 |
Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Isonipecotic Acids; Male; Methylprednisolone; Middle Aged; Nausea; Neoplasms; Ondansetron; Quality of Life; Surveys and Questionnaires; Vomiting | 2005 |
11 other study(ies) available for ondansetron and methylprednisolone
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Compatibility of ondansetron hydrochloride and methylprednisolone sodium succinate in multilayer polyolefin containers.
Topics: Antiemetics; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Incompatibility; Drug Packaging; Drug Stability; Drug Storage; Glucose; Infusions, Intravenous; Methylprednisolone; Ondansetron; Pharmaceutical Solutions; Polyenes; Sodium Chloride; Temperature | 2005 |